Literature DB >> 26967969

Blebbishield emergency program: an apoptotic route to cellular transformation.

G G Jinesh1, A M Kamat1.   

Abstract

Mesh：

Year:  2016        PMID： 26967969      PMCID： PMC4832111          DOI： 10.1038/cdd.2016.26

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  10 in total

1.  N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death.

Authors:  G Gao; Q P Dou
Journal:  J Cell Biochem       Date:  2000-09-18       Impact factor: 4.429

2.  Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.

Authors:  Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Harri P Mankonen; Michael Lilly; Päivi J Koskinen
Journal:  FEBS Lett       Date:  2004-07-30       Impact factor: 4.124

Review 3.  Secondary necrosis: the natural outcome of the complete apoptotic program.

Authors:  Manuel T Silva
Journal:  FEBS Lett       Date:  2010-10-26       Impact factor: 4.124

Review 4.  Bladder cancer stem cells: biological and therapeutic perspectives.

Authors:  G Goodwin Jinesh; Daniel Levi Willis; Ashish M Kamat
Journal:  Curr Stem Cell Res Ther       Date:  2014-03       Impact factor: 3.828

Review 5.  Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis.

Authors:  D Westphal; R M Kluck; G Dewson
Journal:  Cell Death Differ       Date:  2013-10-25       Impact factor: 15.828

6.  Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis.

Authors:  G G Jinesh; W Choi; J B Shah; E K Lee; D L Willis; A M Kamat
Journal:  Cell Death Differ       Date:  2012-11-23       Impact factor: 15.828

7.  Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Authors:  Haoqiang Ying; Alec C Kimmelman; Costas A Lyssiotis; Sujun Hua; Gerald C Chu; Eliot Fletcher-Sananikone; Jason W Locasale; Jaekyoung Son; Hailei Zhang; Jonathan L Coloff; Haiyan Yan; Wei Wang; Shujuan Chen; Andrea Viale; Hongwu Zheng; Ji-hye Paik; Carol Lim; Alexander R Guimaraes; Eric S Martin; Jeffery Chang; Aram F Hezel; Samuel R Perry; Jian Hu; Boyi Gan; Yonghong Xiao; John M Asara; Ralph Weissleder; Y Alan Wang; Lynda Chin; Lewis C Cantley; Ronald A DePinho
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

8.  Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.

Authors:  Goodwin Jinesh G; Srinivas Chunduru; Ashish M Kamat
Journal:  J Leukoc Biol       Date:  2012-04-18       Impact factor: 4.962

9.  Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis.

Authors:  Chi-Wu Chiang; Cindy Kanies; Kwang Woon Kim; Wei Bin Fang; Christina Parkhurst; Minhui Xie; Travis Henry; Elizabeth Yang
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

10.  Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields.

Authors:  Goodwin G Jinesh; Naomi M Laing; Ashish M Kamat
Journal:  Biochem J       Date:  2015-10-27       Impact factor: 3.857
  10 in total
  11 in total

1.  RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program.

Authors:  Goodwin G Jinesh; Ashish M Kamat
Journal:  Cell Death Discov       Date:  2017-05-29

2.  Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Authors:  Yaroslav R Efremov; Anastasia S Proskurina; Ekaterina A Potter; Evgenia V Dolgova; Oksana V Efremova; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Front Genet       Date:  2018-11-16       Impact factor: 4.599

Review 3.  Targeting K-Ras and apoptosis-driven cellular transformation in cancer.

Authors:  Isha Godwin; Nikhil Ponnoor Anto; Smitha V Bava; Mani Shankar Babu; Goodwin G Jinesh
Journal:  Cell Death Discov       Date:  2021-04-14

4.  Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma.

Authors:  Goodwin G Jinesh; Marco Napoli; Marian T Smallin; Andrew Davis; Hayley D Ackerman; Payal Raulji; Nicole Montey; Elsa R Flores; Andrew S Brohl
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.996

5.  Novel PKC-ζ to p47 phox interaction is necessary for transformation from blebbishields.

Authors:  Goodwin G Jinesh; Rikiya Taoka; Qiang Zhang; Siddharth Gorantla; Ashish M Kamat
Journal:  Sci Rep       Date:  2016-04-04       Impact factor: 4.379

6.  Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.

Authors:  Goodwin G Jinesh; Ganiraju C Manyam; Chinedu O Mmeje; Keith A Baggerly; Ashish M Kamat
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

Review 7.  Molecular genetics and cellular events of K-Ras-driven tumorigenesis.

Authors:  G G Jinesh; V Sambandam; S Vijayaraghavan; K Balaji; S Mukherjee
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

Review 8.  Apoptosis: A Target for Anticancer Therapy.

Authors:  Claire M Pfeffer; Amareshwar T K Singh
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

9.  Regulation of MYO18B mRNA by a network of C19MC miRNA-520G, IFN-γ, CEBPB, p53 and bFGF in hepatocellular carcinoma.

Authors:  Goodwin G Jinesh; Marco Napoli; Hayley D Ackerman; Payal M Raulji; Nicole Montey; Elsa R Flores; Andrew S Brohl
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.996

10.  Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers.

Authors:  Goodwin G Jinesh; Elsa R Flores; Andrew S Brohl
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.